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Preoperative cardiac assessment in patients undergoing
major vascular surgery
Nicola Troisi*, Raffaele Pulli*, Walter Dorigo*, Patrizia Lo Sapio† and Carlo Pratesi*
The aim of this study was to evaluate the effectiveness of a preoperative standardized cardiac assessment in patients undergoing
major vascular surgery. From January 2005 to December 2006, 1446 elective interventions for major vascular diseases (carotid
stenosis, CS; abdominal aortic aneurysm, AAA; peripheral arterial obstructive disease, PAOD) were performed; 1090 out of these
patients underwent preoperative diagnostic assessment on an outpatient basis. Thirty-day results in terms of cardiac mortality and
morbidity rates were recorded. Patients suffered from a CS in 578 cases (53%), an AAA in 303 cases (27.8%) and a PAOD in 209 cases
(19.2%). Four hundred thirty-two patients (39.6%) underwent further evaluation of cardiac functional capacity with non-invasive
stress testing. Sixteen patients were successfully treated prior to vascular surgery. Thirty-day cardiac mortality and morbidity rates
were 0.2% and 3.9%, respectively. A positive preoperative non-invasive stress testing did not affect 30-day cardiac outcomes. In
conclusion, the use of an accurate preoperative cardiac assessment allowed us to obtain satisfactory perioperative results in patients
undergoing major vascular surgery. Routine preoperative evaluation with non-invasive stress testing did not seem to improve
perioperative cardiac results.
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Introduction
Cardiac complications (myocardial infarction, acute conges-
tive heart failure, pulmonary edema, fatal arrhythmias) rep-
resent the major cause of perioperative morbidity and
mortality in patients undergoing major vascular surgery.1–4
This is particularly related to the frequent association of sys-
temic localizations of atherosclerosis (carotid bifurcation,
abdominal aorta, peripheral arteries) with coronary artery
disease (CAD).5,6 It has also been demonstrated that history
of CAD, congestive heart failure, cerebrovascular disease, dia-
betes mellitus and chronic renal failure increase perioperative
cardiac mortality and morbidity rates.7,8
In order to reduce perioperative cardiac complications in
patients undergoing major vascular surgery, an accurate
cardiac assessment, consisting of electrocardiogram (ECG),
cardiologist consultation, echocardiography and, in selected
cases, non-invasive stress testing, has been advocated by
several authors.9–11 Non-invasive stress testing, is widely
used in order to assess the risk of cardiac complications in
the perioperative period, even if its predictive power is con-
troversial;10 furthermore, other authors suggested the use of
preoperative cardiac testing only in patients considered at
high surgical risk, omitting it in intermediate-risk
patients.12
The demonstration of a poor cardiac functional capacity
makes necessary the adoption of measures to reduce perio-
perative cardiac risk. Perioperative beta-blocker medical
therapy is associated with a reduced risk of in-hospital
death among patients undergoing major non-cardiac
surgery.13
At the moment, there are no strong data to support pro-
phylactic surgical or endovascular myocardial revasculariza-
tion;9,11,14 hence, myocardial revascularization prior to
vascular surgery should be reserved for those few patients
with unstable angina or stable angina with significant left
main or three-vessel CAD9 (American College of
Cardiology/American Heart Association [ACC/AHA]
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guidelines) or for patients with proven ischemic heart
disease subject to high-risk surgery (European Society of
Cardiology [ESC] guidelines).11
The aim of this study was to evaluate the effectiveness of
a preoperative standardized cardiac assessment in the
reduction of perioperative cardiac morbidity and mortality
rates in patients undergoing major vascular surgery in a
single-center experience.
Methods
From January 2005 to December 2006, 1446 elective open
and endovascular interventions for major vascular diseases
(carotid stenosis, CS; abdominal aortic aneurysm, AAA;
peripheral arterial obstructive disease, PAOD) were per-
formed at our Institution; 1090 out of these patients under-
went preoperative diagnostic and cardiac assessment on an
outpatient basis. We excluded from our series all patients
without a complete preoperative assessment (operation in
emergency/urgency, direct admission at our Department,
transfer from other Departments).
Data from all preoperative evaluations in an outpatient
basis were prospectively collected in a dedicated database,
which included demographic data, preoperative risk factors,
and clinical and diagnostic assessment. All these patients
underwent open or endovascular intervention and perio-
perative (<30 days) results in terms of overall and cardiac
morbidity and mortality rates were recorded.
Preoperative diagnostic assessment
Regardless of the kind of vascular disease, all patients preo-
peratively underwent an extensive assessment of clinical
history and a physical examination, a two-view chest X-ray,
an ECG, laboratory tests including complete blood count,
coagulative parameters and blood chemistries and a duplex
ultrasound scanning of the indexed district. Moreover, all
patients suffering from AAA or PAOD underwent duplex
scanning of the supra-aortic vessels.
Patients assessed with CS preoperative underwent a
computed tomography (CT) scan of cerebral parenchyma
and CT angiography (CTA) of extracranial vessels. Degree
of stenosis was determined by using the North American
Symptomatic Carotid Endarterectomy Trial method.
Patients with AAA underwent CTA of the entire aorta
to evaluate the presence of other aortic lesions and to deter-
mine the type of repair (assessment of criteria of feasibility
for endovascular repair). In this subgroup, in patients with
a history of chronic obstructive pulmonary disease or
asthma, pulmonary functional capacity and response to
bronchodilators were investigated and the presence of
carbon dioxide retention through arterial blood gas analysis
was evaluated.
In patients with PAOD, preoperative diagnostic evalu-
ation was completed by CTA of the lower limbs, reserving
the digital subtraction angiography in double projection in
selected cases.
Finally, regardless of the response of ECG, all patients
underwent cardiological consultation associated with an
echocardiography with evaluation of left-ventricular ejection
fraction (LVEF). Since most of the patients came from per-
ipheral centers, the cardiologist recommended changes in
medications, in order to obtain the best medical treatment
in all patients, consisting of statins and antiplatelet agents in
all patients and beta-blockers in selected cases. A resting
heart rate of 60–65 beats/min was considered right.
Our series comprised patients undergoing carotid, aortic
and peripheral surgery. On the basis of ACC/AHA and ESC
guidelines,9,11 patients undergoing open or endovascular
carotid surgery should be considered at intermediate cardiac
risk (between 1% and 5%) and patients undergoing open
aortic and peripheral surgery should be considered at high
cardiac risk (>5%); furthermore, patients undergoing endo-
vascular aortic or peripheral surgery should be considered
at intermediate cardiac risk (between 1% and 5%). The car-
diologist performed the consultation before the surgeon had
decided what was the kind of treatment for the patient
(open or endovascular); hence, all patients subject to aortic
or peripheral surgery have been considered at high surgical
risk and the decision to make further preoperative tests was
taken by the cardiologist on the basis of the results of
history, physical examination, ECG and echocardiography.
In particular, the cardiologist suggested non-invasive
stress testing in the presence of past or recent ischemic
heart disease, compensated or prior heart failure, past or
recent cerebrovascular disease, diabetes mellitus, chronic
renal failure (history); alterations at cardiac auscultation
(physical examination); significant arrhythmias, abnormal
Q waves (ECG anomalies); and severe valvular diseases,
abnormal areas of motility, LVEF less than 40% (echocar-
diographic anomalies). All non-invasive stress tests have
been conducted after withdrawal of beta-blockers.
In patients with a negative cardiac stress test, surgery
was performed without any other investigation. Patients
with a positive stress test (a peak heart rate less than 85% of
the maximum predicted at dobutamine stress echocardio-
graphy or reversible defects that involved more than 20% of
myocardial segments at the radionuclide myocardial
perfusion imaging) underwent new consultation and the
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cardiologist, also on the basis of the surgeon’s decision, pro-
posed higher levels of postoperative care in the intensive
care unit (ICU) and further changes in medications with
the adjunct of beta-blockers or suggested performing classi-
cal coronary angiography with possible therapeutic pro-
cedures (percutaneous transluminal coronary angioplasty
[PTCA] or coronary artery bypass graft [CABG]). Coronary
revascularization prior to vascular surgery was performed in
patients subject to high-risk surgery, who had unstable
angina or stable angina with three-vessel disease or a signifi-
cant stenosis of the left main coronary artery.
In these patients the vascular intervention was conse-
quently delayed. If PTCA was performed, patients received a
single antiplatelet therapy (aspirin) for four weeks. If a stent
was inserted, a dual antiplatelet therapy was administered
(aspirin and clopidogrel) for four weeks (bare-metal coron-
ary stents) or six months (drug-eluting coronary stents).
Definition of parameters
Our database included demographic data, preoperative risk
factors, and clinical and diagnostic assessment. We used
some criteria to define these parameters, as shown in
Table 1.
Statistical analysis
Statistical analysis was performed by using SPSS 15.0 for
Windows (SPSS Inc, Chicago, IL, USA). General character-
istics, cardiovascular risk factors, results of preoperative
diagnostic assessment and different surgical approaches for
perioperative (<30 days) cardiac mortality and morbidity
rates were analyzed and compared by χ2 test or Fisher’s
exact test when necessary. Statistical significance was
defined at the P < 0.05 level.
Table 1 Parameters used to elaborate the perioperative cardiac risk
Parameter Definition
Sex Male/female
Older age >80 y
Smoking Current or previous (within 10 y) smoker
Hypertension A systolic blood pressure of 140 mmHg or greater, a diastolic blood pressure of 90 mmHg or
greater or use of antihypertensive medications
Hypercholesterolemia Total cholesterol serum level >200 mg/dL or low-density lipoprotein (LDL) cholesterol >140 mg/dL
or use of statins
Diabetes mellitus Fasting glucose of 126 mg/dL or greater or use of oral antidiabetics/insulin
Chronic obstructive pulmonary
disease
Chronic parenchymal X-ray changes or pulmonary function tests less than 80% of predicted
Chronic renal failure Creatinine serum level greater than 2.0 mg/dL
Coronary artery disease History of at least one of the following: positive ECG changes consistent with myocardial ischemia,
angina, myocardial infarction, PTCA and CABG
Myocardial infarction History of previous myocardial infarction
PTCA History of previous myocardial endovascular revascularization
CABG History of previous myocardial surgical revascularization
Congestive heart failure Presence of any of the following: history of congestive heart failure, pulmonary edema or
paroxysmal nocturnal dyspnea, bilateral rales or S3 gallop at physical examination, pulmonary
vascular redistribution at chest radiograph
Valvular heart disease Presence of any of the following: echocardiographic features – aortic stenosis with a maximal jet
velocity ≥2.5 m/s, mitral stenosis with a valve area ≤2 cm2, aortic regurgitation with a grade ≥2/4,
mitral regurgitation with a grade ≥2/4, patients who have undergone any intervention on a
cardiac valve
Arrhythmia Presence of any of the following: atrial fibrillation, high-grade atrioventricular block, ventricular or
supraventicular ectopy
Implanted devices Presence of a pace-maker or an implantable cardioverter defibrillator (ICD)
Positive stress testing Poor cardiac functional capacity diagnosed at radionuclide myocardial perfusion imaging or
dobutamine stress echocardiography or treadmill exercise test
Cardiac treatment PTCA or CABG prior to vascular surgery
ECG, electrocardiogram; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty
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Results
Study group
Patients were predominantly men (831, 76.2%), with a mean
age of 72.4 years (range 32–92). They suffered from CS in
578 cases (53%), AAA in 303 cases (27.8%) and PAOD in
209 cases (19.2%). Demographic data, preoperative risk
factors and clinical assessment are shown in Table 2.
Preoperative cardiac assessment
According to our decisional algorithm, 658 patients (60.4%)
without anomalies at ECG, cardiological consultation and
echocardiography underwent surgical vascular intervention
without any other diagnostic assessments. The remaining
432 patients (39.6%) underwent further evaluation of
cardiac functional capacity with a dobutamine stress echo-
cardiography in 272 cases (63%), a radionuclide myocardial
perfusion imaging in 140 cases (32.4%) and a maximal
treadmill exercise test according to the Bruce protocol in 20
patients (4.6%).
Of these 432 patients, 326 (75.5%) had a negative test,
while the remaining 106 patients (24.5%) had a positive
one. In 73 (68.9%) out of these 106 patients, perioperative
cardiological risk was judged acceptable by the consultant
and beta-blocker medical therapy and postoperative ICU
stay were suggested. In the remaining 33 patients (31.1%), a
coronary angiography was performed; no significant CAD
was diagnosed in 17 cases and the patients were operated
on, while the remaining 16 patients had significant coronary
artery lesions and were successfully treated (15 PTCA and 1
CABG) prior to vascular surgery (Table 3).
Operative management
Concerning the CS group, a standard carotid endarterect-
omy according to the technique of early distal control of the
internal carotid artery15 with extensive use of patch and
selective use of shunt was performed in 552/578 cases
(95.5%), while the remaining 26 patients (4.5%) underwent
carotid artery stenting (CAS). For the AAA group, tra-
ditional open repair with a standard transperitoneal
approach was carried out in 180/303 patients (59.4%), while
in the other 123 cases (40.6%) AAA was excluded through
the endovascular implantation of a stent-graft. Finally, in
PAOD patients the endovascular approach was performed
in 101/209 cases (48.3%).
Overall, 125 patients (11.5%) required a higher level of
postoperative monitoring in ICU.
A beta-blocker therapy was continued in all patients
who received it prior to the cardiological assessment.
Furthermore, with regard to cardiac management, the
surveillance for perioperative myocardial infarction was
Table 2 Demographic data, preoperative risk factors and clinical assessment
CS group (n = 578) AAA group (n = 303) PAOD group (n = 209) Total (n = 1090)
Male sex 411 (71.1%) 272 (89.8%) 148 (70.8%) 831 (76.2%)
Median age (y) 73.1 72.5 70.1 72.4
Older age (>80 y) 131 (22.7%) 60 (19.8%) 31 (14.8%) 222 (20.4%)
Smoking 415 (71.8%) 278 (91.7%) 177 (84.7%) 870 (79.8%)
Hypertension 440 (76.1%) 208 (68.6%) 153 (73.2%) 801 (73.5%)
Hypercholesterolemia 315 (54.5%) 105 (34.7%) 118 (56.5%) 538 (49.4%)
Diabetes mellitus 143 (24.7%) 32 (10.6%) 69 (33%) 244 (22.4%)
Chronic obstructive pulmonary disease 199 (34.4%) 207 (68.3%) 75 (35.9%) 481 (44.1%)
Renal chronic failure 61 (10.6%) 30 (9.9%) 15 (7.2%) 106 (9.7%)
Coronary artery disease 127 (22%) 83 (27.4%) 61 (29.2%) 271 (24.9%)
Myocardial infarction 83 (14.4%) 52 (17.2%) 48 (23%) 183 (16.8%)
PTCA 39 (6.7%) 26 (8.6%) 20 (9.6%) 85 (7.8%)
CABG 41 (7.1%) 19 (6.3%) 21 (10%) 81 (7.4%)
Congestive heart failure 12 (2.1%) 18 (5.9%) 14 (6.7%) 44 (4%)
Valvular heart disease 65 (11.2%) 27 (8.9%) 21 (10%) 113 (10.4%)
Arrhythmia 99 (17.1%) 49 (16.2%) 39 (18.7%) 187 (17.2%)
Implanted devices 19 (3.3%) 7 (2.3%) 9 (4.3%) 35 (3.2%)
CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; CS, carotid stenosis; PAOD, peripheral arterial obstructive
disease; AAA, abdominal aortic aneurysm
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obtained with the measurement of troponin T in the recov-
ery room after operation and on the next two postoperative
mornings; if indicated, the troponin T monitoring was con-
tinued. The diagnosis of myocardial infarction was deter-
mined by troponin T values combined with either changes
on ECG or symptoms referred by the patient.
Early results (<30 days)
In our series, two open-treated patients died in the early
postoperative period for an acute congestive heart failure
with pulmonary edema. As a consequence, 30-day cardiac
mortality rate was 0.2% (2/1090 patients). Analyzing the
three categories of patients, there were no differences in
terms of 30-day cardiac mortality risk (Table 4).
At univariate analysis, in the AAA group, valvular heart
disease and history of previous congestive heart failure rep-
resented factors significantly affecting 30-day cardiac mor-
tality (Table 5). Multivariate analysis did not confirm the
significance for any of the examined parameters. Moreover,
at 30 days, 81 patients (7.4%) had a major complication,
requiring a prolonged hospital stay or a re-intervention: 45
had at least one cardiac complication (22 myocardial infarc-
tions requiring a PTCA in 11 cases, 16 episodes of atrial
fibrillation and 7 of acute congestive heart failure) with a
30-day cardiac morbidity rate of 4.1% (Table 4). In the 22
patients with a postoperative myocardial infarction, none of
the examined factors showed an increased risk at uni- and
multivariate analysis.
Furthermore, the AAA group showed an increased risk
of overall and cardiac 30-day morbidity rates with respect to
other patients. In particular, univariate analysis showed that
at ages older than 80 years, chronic renal failure and valvu-
lar heart disease significantly affect 30-day cardiac morbid-
ity (Table 6); chronic renal failure and valvular heart disease
maintained their significance also at multivariate analysis
(P = 0.01, 95% CI: 1.3–12.1; P = 0.002, 95% CI: 1.8–15.5,
respectively).
Discussion
Historically, many attempts to obtain a precise cardiac risk-
score following major vascular surgery have been made;7,16, 17
in these studies, history of CAD, congestive heart failure,
cerebrovascular disease, diabetes mellitus and chronic renal
failure increased the risk of perioperative cardiac adverse
events. Also in our patients undergoing aortic surgery,
several preoperative risk factors affected cardiac mortality
and morbidity (valvular heart disease, history of previous
congestive heart failure, age older than 80 years and chronic
renal failure).
Table 3 Preoperative cardiac assessment and operative management
CS group (n = 578) AAA group (n = 303) PAOD group (n = 209) Total (n = 1090)
Stress testing 135/578 (23.4%) 222/303 (73.3%) 75/209 (35.9%) 432/1090 (39.6%)
Positive stress testing 31/135 (23%) 56/222 (25.2%) 19/75 (25.3%) 106/432 (24.5%)
Coronary angiography 11/31 (35.5%) 17/56 (30.4%) 5/19 (26.3%) 33/106 (31.1%)
PTCA 4/31 (12.9%) 8/56 (14.3%) 3/19 (15.8%) 15/106 (14.1%)
CABG 1/31 (3.2%) 0 0 1/106 (0.9%)
Endovascular treatment 26/578 (4.5%) 123/303 (40.6%) 101/209 (48.3%) 250/1090 (22.9%)
Postoperative ICU 31/578 (5.4%) 73/303 (24.1%) 21/209 (10%) 125/1090 (11.5%)
CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; CS, carotid stenosis; PAOD, peripheral arterial obstructive
disease; AAA, abdominal aortic aneurysm; ICU, intensive care unit
Table 4 Early results (<30 days)
CS group (n = 578) AAA group (n = 303) PAOD group (n = 209) P Total (n = 1090)
Cardiac mortality 0 2 (0.7%) 0 NS 2/1090 (0.2%)
Cardiac morbidity 14 (2.4%) 23 (7.6%) 8 (3.8%) 0.001 45/1090 (4.1%)
7 myocardial infarction 9 myocardial infarction 6 myocardial infarction
6 atrial fibrillation 9 atrial fibrillation 1 atrial fibrillation
1 congestive heart failure 5 congestive heart failure 1 congestive heart failure
CS, carotid stenosis; PAOD, peripheral arterial obstructive disease; AAA, abdominal aortic aneurysm; NS, non-significant
Between AAA group and the other two groups
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Table 6 AAA group: univariate analysis for cardiac morbidity at 30
days
AAA group
(23 complications) (%) P
Sex
Male 7
Female 9.7 NS
Age (y)
<80 5.4 0.01
>80 15
Smoking
Yes 6.5 NS
No 16
Hypertension
Yes 6.7 NS
No 8.4
Hypercholesterolemia
Yes 4.8 NS
No 8.6
Diabetes mellitus
Yes 9.4 NS
No 7
Chronic obstructive
pulmonary disease
Yes 7.7 NS
No 6.2
Chronic renal failure
Yes 20 0.005
No 5.8
Coronary artery disease
Yes 7.2 NS
No 7.3
Congestive heart failure
Yes 16.7 NS
No 6.7
Valvular heart disease
Yes 25.9 <0.001
No 5.4
Arrhythmia
Yes 8.2 NS
No 7.1
Implanted devices
Yes 14.3 NS
No 7.1
Positive stress testing
Yes 8.9 NS
No 4.8
Cardiac treatment
Yes 0 NS
No 6.1
Endovascular treatment
Yes 4.1 NS
No 9.4
NS, non-significant; AAA, abdominal aortic aneurysm
Table 5 AAA group: univariate analysis for cardiac mortality at 30
days
AAA group
(2 deaths) (%) P
Sex
Male 0.7 NS
Female 0
Age (y)
<80 0.4 NS
>80 1.7
Smoking
Yes 0.7 NS
No 0
Hypertension
Yes 1 NS
No 0
Hypercholesterolemia
Yes 1.9 NS
No 0
Diabetes mellitus
Yes 3.1 NS
No 0.4
Chronic obstructive
pulmonary disease
Yes 0.5 NS
No 1
Chronic renal failure
Yes 3.3 NS
No 0.4
Coronary artery disease
Yes 1.2 NS
No 0.4
Congestive heart failure
Yes 5.6 <0.01
No 0.3
Valvular heart disease
Yes 3.7 0.04
No 0.4
Arrhythmia
Yes 0 NS
No 0.8
Implanted devices
Yes 0 NS
No 0.7
Positive stress testing
Yes 0 NS
No 0.6
Cardiac treatment
Yes 0 NS
No 0.5
Endovascular treatment
Yes 0 NS
No 1.1
NS, non-significant; AAA, abdominal aortic aneurysm
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In 1996, the ACC/AHA published the first clinical
guidelines for preoperative cardiac risk stratification in
patients undergoing non-cardiac surgery. These guidelines
were recently updated in 2007.9 Other societies published
their own guidelines11,18,19 and numerous discrepancies
exist between them.20
In particular, comparing the most updated guidelines
(ACC/AHA 2007 and ESC 2009),9,11 there were no substan-
tial differences in the stratification of the risk in major vas-
cular surgery; in fact, both considered at high surgical risk
all patients undergoing open aortic and peripheral surgery
and at intermediate surgical risk all patients subject to
carotid surgery (open or endovascular) or to endovascular
aortic/peripheral procedures. Our approach did not substan-
tially differ from these classifications, but our patients
underwent cardiological consultation before the surgeons
and the patients decided the best type of treatment and so
we considered all patients suffering from aortic/peripheral
diseases as high surgical risk patients. This represents a real
problem in clinical practice, which is often omitted in the
official guidelines.
Furthermore, ACC/AHA 2007 and ESC 2009 guidelines
recommended the selective use of supplemental preoperative
non-invasive cardiac testing in order to provide an objective
measure of cardiac functional capacity, to identify the pres-
ence of significant myocardial ischemia and to evaluate the
risk of perioperative cardiac adverse outcomes; however,
some differences exist. In fact, American guidelines rec-
ommended the use of non-invasive stress testing in patients
with active cardiac conditions and in patients subject to all
vascular procedures with three or more clinical factors, and
suggested its utilization in patients subject to all vascular
procedures with at least one clinical factor. On the other
hand, European guidelines recommended a supplemental
stress testing in patients subject to high-risk surgery (open
aortic and peripheral diseases) with three or more clinical
factors and suggested its utilization in patients considered
at intermediate risk (carotid procedures). Our data were
prospectively collected from January 2005 to December
2006; hence, we could not follow any of these guidelines.
However, our approach was quite similar to the recommen-
dations and suggestions reported by ACC/AHA guidelines.
A particular key point is the need to perform a sup-
plemental preoperative cardiac testing in patients subject to
carotid surgery (considered in both guidelines at intermedi-
ate risk); the DECREASE (Dutch Echographic Cardiac Risk
Evaluation Applying Stress Echo) II trial12 demonstrated
that cardiac testing could safely be omitted in
intermediate-risk patients, provided that beta-blocker
therapy aiming at tight heart rate control is prescribed. In
our series, we performed 135 cardiac stress testings in
the 578 patients subject to carotid surgery, and according
to the conclusions of the DECREASE II trial, these
further evaluations could have been avoided, saving time and
economical resources. Furthermore, only 31/135 patients
(23%) had a positive stress test and five patients (3.7%)
underwent preoperative myocardial revascularization; in these
five patients no perioperative cardiac complications occurred,
but we cannot know what could have happened in these
patients if left untreated. Hence, our experience supports the
conclusions of this randomized trial.
Several authors21–24 demonstrated that positive predic-
tive value of stress testing is very poor (5–25%) and they
concluded that its use in order to predict perioperative
cardiac events is very limited. Our experience supports these
conclusions; in our population study, a positive preoperative
cardiac stress testing does not represent a risk factor for
postoperative cardiac events and its positive predictive
power is very low.
As a consequence, a positive preoperative non-invasive
cardiac stress testing seems to support the value of appropriate
perioperative medical therapies in order to lower the cardiac
risk rather than extensive use of myocardial revascularization.
The guidelines9,11 suggested that beta-blockers should be
given to patients undergoing major vascular surgery, but the
most recent POISE trial25 minimized the benefits resulting in
the assumption of beta-blocker medical therapy in the perio-
perative period. In our experience, beta-blocker medical
therapy and a high level of postoperative care in ICU is the
most used approach in patients with poor cardiac functional
capacity undergoing endovascular treatment.
Controversial data exist also about benefits of myocardial
revascularization in reducing perioperative cardiac adverse
events in patients undergoing major vascular surgery;9,11,12
ACC/AHA 2007 guidelines stated that coronary revasculari-
zation before non-cardiac surgery is useful in patients with
stable angina and significant left main coronary artery ste-
nosis or a three-vessel disease or in patients with unstable
angina, while ESC 2009 guidelines recommended a prophy-
lactic myocardial revascularization prior to high-risk
surgery in patients with proven ischemic heart disease and
not in patients at intermediate risk. In our series, about
one-third of patients (33/106, 31.1%) with positive stress
testing underwent coronary angiography; one of the treated
patients had a postoperative myocardial infarction, while in
the untreated group no cardiac complications occurred. So,
preoperative coronary revascularization did not seem to be
useful for reducing perioperative cardiac risk.
In the AAA subgroup, endovascular techniques allow
the treatment of patients whose co-morbidities make
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conventional open repair difficult or high risk. For this
reason, patients with a positive test could be treated with
endovascular treatment when anatomically feasible. In our
experience, endovascular treatment reduced cardiac morbid-
ity rates compared with open surgical repair, even if these
differences did not reach the statistical significance.
However, this should encourage many surgeons to stress the
indications for endovascular treatment.
Finally, this study has some limits: our results were
carried out on a small monocentric sample size and we ana-
lyzed a heterogeneous population including patients under-
going vascular interventions at different levels of
perioperative cardiac risk; in fact, patients undergoing
abdominal aortic surgery showed higher cardiac morbidity
and mortality rates than the other two groups. Furthermore,
our overall 30-day outcomes in terms of mortality and
major morbidity seemed to be better than others reported
in previously published series. Maybe our good 30-day out-
comes suffered from a selection bias; in fact, in our series
we enrolled only the patients completely assessed in the pre-
operative period on an outpatient basis and we excluded all
patients without a complete preoperative assessment. The
strict respect of the worldwide accepted indications and the
close collaboration with cardiologists and internists in the
selection and the care of our patients may have contributed
to our very good results in this subset of patients as well.
So, in conclusion, in our experience the use of an accurate
preoperative cardiac assessment allowed us to obtain satisfac-
tory perioperative results in patients undergoing major vascu-
lar surgery. Patients with AAAs represented a subgroup with
higher perioperative cardiac morbidity rates. Routine preo-
perative evaluation with non-invasive stress testing did not
seem to improve perioperative cardiac results in any subgroup
treated for vascular diseases. However, the selective use of
stress testing made it possible to identify a subgroup of higher
risk patients who could benefit from coronary angiography
and possible treatment of their CAD.
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